Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TriSalus Life Sciences (TLSI) Net Margin (2022 - 2026)

TriSalus Life Sciences has reported Net Margin over the past 5 years, most recently at 17.29% for Q1 2026.

  • For Q1 2026, Net Margin rose 13824.0% year-over-year to 17.29%; the TTM value through Mar 2026 reached 130.32%, down 3600.0%, while the annual FY2025 figure was 154.35%, 4143.0% down from the prior year.
  • Net Margin for Q1 2026 was 17.29% at TriSalus Life Sciences, up from 73.86% in the prior quarter.
  • Over five years, Net Margin peaked at 17.29% in Q1 2026 and troughed at 786.45% in Q4 2022.
  • A 5-year average of 226.58% and a median of 131.84% in 2024 define the central range for Net Margin.
  • Biggest five-year swings in Net Margin: surged 50510bps in 2024 and later tumbled -31329bps in 2025.
  • Year by year, Net Margin stood at 786.45% in 2022, then grew by 19bps to 636.93% in 2023, then surged by 79bps to 131.84% in 2024, then skyrocketed by 44bps to 73.86% in 2025, then soared by 123bps to 17.29% in 2026.
  • Business Quant data shows Net Margin for TLSI at 17.29% in Q1 2026, 73.86% in Q4 2025, and 356.86% in Q3 2025.